Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

por Zierhut, ML, Chen, Y, Pithavala, YK, Nickens, DJ, Valota, O, Amantea, MA
Publicado 2016

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.

por Negri, D. R., Tosi, E., Valota, O., Ferrini, S., Cambiaggi, A., Sforzini, S., Silvani, A., Ruffini, P. A., Colnaghi, M. I., Canevari, S.
Publicado 1995

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

por Fokkema, E, Verweij, J, van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, de Vries, E G E, Groen, H J M
Publicado 2000

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

por Gross-Goupil, M, Kwon, T G, Eto, M, Ye, D, Miyake, H, Seo, S I, Byun, S -S, Lee, J L, Master, V, Jin, J, DeBenedetto, R, Linke, R, Casey, M, Rosbrook, B, Lechuga, M, Valota, O, Grande, E, Quinn, D I
Publicado 2018